These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 39222176)

  • 1. PSMD2 overexpression as a biomarker for resistance and prognosis in renal cell carcinoma treated with immune checkpoint and tyrosine kinase inhibitors.
    Xu X; Wang J; Wang Y; Zhu Y; Wang J; Guo J
    Cell Oncol (Dordr); 2024 Oct; 47(5):1943-1956. PubMed ID: 39222176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma.
    Xu X; Lin J; Wang J; Wang Y; Zhu Y; Wang J; Guo J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2350101. PubMed ID: 38738709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression.
    Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
    Cancer Res Treat; 2023 Oct; 55(4):1321-1336. PubMed ID: 37024096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
    Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
    Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients.
    Xu X; Wang Y; Hu X; Zhu Y; Wang J; Guo J
    Neoplasia; 2023 Sep; 43():100919. PubMed ID: 37517099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
    Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
    Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression.
    Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
    Immunogenetics; 2023 Apr; 75(2):133-143. PubMed ID: 36515717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma.
    Wang J; Lin J; Wang J; Wang Y; Zhu Y; Xu X; Guo J
    Discov Oncol; 2024 Mar; 15(1):86. PubMed ID: 38519766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
    Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
    Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety.
    Yanagisawa T; Mori K; Kawada T; Katayama S; Uchimoto T; Tsujino T; Nishimura K; Adachi T; Toyoda S; Nukaya T; Fukuokaya W; Urabe F; Murakami M; Yamanoi T; Bekku K; Komura K; Takahara K; Hashimoto T; Fujita K; Azuma H; Ohno Y; Shiroki R; Uemura H; Araki M; Kimura T;
    Urol Oncol; 2024 Nov; 42(11):374.e21-374.e29. PubMed ID: 39085019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy for renal cell carcinoma with inferior vena cava tumor thrombosis.
    Yoshida K; Nagasaka N; Kondo T; Kobari Y; Ishihara H; Fukuda H; Iizuka J; Ishida H; Takagi T
    Int J Clin Oncol; 2024 Oct; 29(10):1538-1547. PubMed ID: 39110357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
    Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
    Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma.
    Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
    Urol Oncol; 2023 Jan; 41(1):51.e13-51.e23. PubMed ID: 36328922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
    Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
    Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
    Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.
    Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M
    Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.
    Fumarola C; La Monica S; Bonelli M; Zoppi S; Alfieri R; Galetti M; Gnetti L; Campanini N; Pozzi G; Cavazzoni A; Mazzaschi G; Silini EM; Buti S; Petronini PG
    Biochem Pharmacol; 2024 Aug; 226():116397. PubMed ID: 38944394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.